Navigation Links
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Date:4/26/2009

/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial(1)

The large EPIC3 clinical study program includes a prospective trial designed to assess the efficacy and tolerability of long-term, low-dose maintenance therapy with PEGINTRON 0.5 mcg/kg/week in patients who previously failed treatment with any alfa-interferon plus ribavirin combination therapy. A total of 631 patients were randomized to PEGINTRON or observational control. Of these, 454 patients were from the retreatment study portion of the EPIC3 program and 172 were direct enrollers into the maintenance study. The primary efficacy measure for the study was time to development of first clinical event, defined as liver decompensation (variceal bleeding, Child-Pugh class C, grade 2 or higher hepatic encephalopathy, ascites requiring therapeutic paracentesis and/or additional therapy), development of hepatocellular carcinoma (HCC), liver transplantation or death. All events other than transplantation and death were adjudicated by an independent committee of experts blinded to the study arm. The secondary efficacy analyses included time to disease progression, including additional events of Child-Pugh class B, emergence of varices and enlargement of pre-existing varices requiring additional therapy.

In the primary efficacy analysis, 36 patients in the control arm and 27 in the treatment arm had clinical events (P=0.14), a non-statistically significant difference. However, in the secondary efficacy analysis there were 87 clinical events in the control arm and 63 in the treatment arm (P=0.01), a statistically significant difference. The main events causing the difference on secondary analysis were emergence or enlargement of varices (43 control vs. 16 treatment). In patients with pre-existing esophageal varices (n=82) there were significantly more events (n=14) in the observation arm compared to the treatment arm (n=4) (P=0.01). Overall the safet
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Pa. , Sept. 2, 2015 ... increases, diversifies revenue base with highly profitable specialty ... , Near-term growth potential with 11 product ... include Paragraph IV certifications  , Provides medium ... candidates in development, including eight controlled substances ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has announced ... UK - November 19-20, 2015)" conference to their ... cover industry case studies, regulatory updates, latest therapies and ... Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar Pharma ...
(Date:9/2/2015)... 2, 2015  Seeger Weiss LLP is reporting that ... commence October 13, 2015. Since the ... approval program, Zimmer NexGen knee implant surpassed FDA investigation ... companies provide evidence that the product is substantially similar ... gain permissions. In 2001, Zimmer began ...
Breaking Medicine Technology:Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 2Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 3Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 4Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 5Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion 6Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... When looking at the types of people ... into one of two categories: those that have a weak appetite or those that have ... still want to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. ...
(Date:9/3/2015)... ... 03, 2015 , ... Leading post-acute electronic medical record (EMR) ... joining the company’s executive leadership team as VP of Product and as VP ... healthcare product and project management. He has been with HealthWyse since 2000 in ...
(Date:9/2/2015)... ... , ... The Aspen Clinic (TAC), located in Basalt, Colorado, today ... inspiring wellness in the Roaring Fork Valley and beyond. , Amanda Wagner, Executive Director ... to fitness - we are much more than a gym. Our fitness and ...
(Date:9/2/2015)... ... 03, 2015 , ... Each year, the editors of Modern ... activists, corporate executives, entrepreneurs, health care professionals, and others have had the most ... magazine to tap the National League for Nursing’s outspoken CEO, Beverly Malone ...
(Date:9/2/2015)... ... 2015 , ... Healthegy, a leading producer of conferences, podcasts ... deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ) ... Larry Renfro, CEO of Optum, will deliver the morning address. In his post, ...
Breaking Medicine News(10 mins):Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 2Health News:Leading Post-Acute EMR Provider HealthWyse Names Bob Anders as VP Product and Kelley Chapman VP Engineering 3Health News:TAC Introduces New Retreats for Fall Fitness 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3
... a colourless, odourless and tasteless chemical element - could ... ,Patients with chronic obstructive pulmonary disease (COPD) have ... the lungs at the end of each breath. This ... reasons for shortness of breath experienced by these patients, ...
... Here’s the good news, the bad news, and some more ... Americans, according to one recent study) are satisfied// with their ... way of having a good sex life, from prescription medication ... ,In many cases, physicians can work with their patients to ...
... Andhra Pradesh and Tamil Nadu will upgrade their existing ... ,"It has been decided to upgrade the hospitals in ... Vice Admiral surgeon Vijay K. Singh, director general of ... ,Singh said a Rs.3-billion budget has been sanctioned, ...
... one in three children in California is overweight or at ... health insurance company.// ,There are even more ... satellite cities. ,The number of overweight children ... rest of California, and nearly doubles the national rate, said ...
... Jammu and Kashmir by humanitarian group Médecins Sans Frontières (MSF) ... and more than one in 10 had been victims of ... ,The report by the Holland-based MSF is based on ... in mid-2005. The survey group defined 1989 as the beginning ...
... have made a Startling discovery. The researchers who want ... their intake of calories is restricted have found that ... on longevity in the fruit flies. ,Scientists ... increase the lifespan of many species, but the mechanism ...
Cached Medicine News:Health News:Helium Helps COPD Sufferers to Exercise 2Health News:Health Issues That Can Impact Sexual Satisfaction 2Health News:Health Issues That Can Impact Sexual Satisfaction 3Health News:Health Issues That Can Impact Sexual Satisfaction 4Health News:South India to Have Modern Military Hospitals 2Health News:Mental Health of Kashmiris Needs Urgent Attention: Survey 2Health News:Food Odors Linked With Lifespan in Fruit Flies 2Health News:Food Odors Linked With Lifespan in Fruit Flies 3Health News:Food Odors Linked With Lifespan in Fruit Flies 4Health News:Food Odors Linked With Lifespan in Fruit Flies 5
... With the increase in Endoscopic cases it is ... Monitor with the Surgical Light. This combination ... without having to adopt an uncomfortable pose. ... including the NUVO Monitoring System. As such ...
... This configuration offers all the performance of a ... perfectly for use in Outpatient Settings, Minor Procedure ... Mounting two single lights either side of the ... in a General OR when combining Flat Screen ...
A Western Blot Immunassay for the detection of antibodies to primarily anti-myelin associated glycoproteins (anti-MAG) and other glycolipid autoantibodies in human serum....
Triturus® is an open and completely automated ELISA immunoassay analyzer which can perform a variety of different tests on a series of samples and process several batches simultaneously....
Medicine Products: